Eric Warren, serving as the Chief Commercial Officer for Mineralys Therapeutics, Inc. (NASDAQ: MLYS), has finalized the disposition of 104,124 shares of the company's common equity. Executed on June 26, 2026, the total value of this transaction reached approximately $2,696,322. The sale was conducted in accordance with a pre-arranged Rule 10b5-1 trading plan, a mechanism designed to facilitate stock transactions while adhering to regulatory compliance standards. Mr. Warren originally adopted this specific trading plan on March 27, 2026.
The execution of the sale involved a weighted-average price point of $25.8953 per share. Individual sale prices within this transaction ranged from a low of $25.8941 to a high of $25.9100. Simultaneously with the sale of these shares, Mr. Warren undertook the acquisition of 104,124 shares of common stock through the exercise of stock options. The exercise price for these options was set at $13.24 per share, resulting in a total cost of $1,378,601. The vesting schedule for these stock options was structured such that 25% of the underlying shares vested on the first anniversary of the grant date. The remaining shares were scheduled to vest in 36 substantially equal monthly installments following that initial vesting event.
Following the completion of these transactions, Mr. Warren's direct ownership in Mineralys Therapeutics common stock stands at 38,400 shares. This insider activity occurs against a backdrop of significant corporate developments and market movements for MLYS. The stock has experienced a substantial surge of nearly 99% over the past year. Despite this recent performance, current trading levels for MLYS remain above its Fair Value estimate, as indicated by InvestingPro analysis. The company's financial health is rated as FAIR, characterized by a balance sheet that holds more cash than debt.
In parallel with the insider transaction, Mineralys Therapeutics has been actively engaged in major financing activities. The company recently announced the pricing of a public offering comprising 5,660,378 shares of common stock, priced at $26.50 per share. This offering is expected to generate approximately $150 million in gross proceeds. Furthermore, the company has secured up to $750 million through a combination of debt, equity, and royalty deals. The strategic objective of these financial maneuvers is to repurchase royalty obligations and strengthen the company's balance sheet.
A critical component of this financial strategy involves a transaction with Tanabe Pharma Corporation. Mineralys will pay an upfront sum of $200 million to Tanabe Pharma, with the potential for an additional $100 million payment upon the achievement of specific commercial milestones. This arrangement is designed to eliminate future royalty payments associated with lorundrostat, the company's lead therapeutic candidate.
Market analyst activity surrounding MLYS reflects ongoing scrutiny of the company's clinical and commercial trajectory. Jefferies has reiterated a Hold rating for the stock, assigning a price target of $30.00. The analyst firm noted potential acquisition interest as Mineralys's new drug application remains under review by the FDA. Meanwhile, H.C. Wainwright has maintained a Buy rating with a more optimistic price target of $56.00. H.C. Wainwright highlighted the presentation of post hoc analysis from the Launch-HTN trial at a recent European medical meeting. This analysis focused on lorundrostat, specifically evaluating its efficacy in patients with uncontrolled or resistant hypertension.
Additionally, Mineralys presented clinical data at the same European meeting, detailing the effects of lorundrostat on patients with chronic kidney disease. The data indicated that 71% of the participants in this study were on multiple anti-hypertensive medications. These clinical presentations and the company's aggressive financial restructuring underscore Mineralys's efforts to advance its therapeutic pipeline and secure its financial position. The stock currently trades at $26.99, reflecting a change of +0.11 (+0.41%) in closed trading. After-hours trading shows a price of $26.98 with no change.